RBPJL and esophageal squamous cell carcinoma: More ESCC patient samples would be required to identify the value of RBPJL (p.P476S) as a potential new predictor for evaluating the efficacy of anti‐PD‐1 therapy, in order to explore the therapeutic values of PD‐1 inhibitors.